DRG Epidemiology's coverage of male hypogonadism comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the prevalence of male hypogonadism for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe and Japan in this report.
DRG Epidemiology's male hypogonadism forecast will answer the following questions:
- Of all people with male hypogonadism, how many in each country across the major mature pharmaceutical markets have been formally diagnosed?
- Of all people diagnosed with male hypogonadism, how many in each country across the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of male hypogonadism over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following male hypogonadism patient populations:
- Male Hypogonadism Total Prevalent Cases
- Comorbidity subpopulation(s)
- Symptomaticity subpopulation(s)
- Primary and Secondary Male Hypogonadism subpopulation(s)
- Diagnosed subpopulation(s)
- Treatment subpopulation(s)
Note: coverage may vary by country and region.
- Male Hypogonadism - Epidemiology - Mature Markets Data
- Key Findings
- Key Updates
- Total Prevalence of Male Hypogonadism per 100 People Aged 40+ in 2018 and 2038
- Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Male Hypogonadism over the Next 20 Years
- Analysis of the Prevalent Cases of Male Hypogonadism in 2018 by Subtype
- Epidemiology Data
- Total Prevalent Cases of Male Hypogonadism
- Diagnosed Prevalent Cases of Male Hypogonadism
- Symptomatic Male Hypogonadism
- Drug-Treated Prevalent Cases of Male Hypogonadism
- Comorbidities of Male Hypogonadism
- Subtypes of Male Hypogonadism
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Male Hypogonadism
- Studies Excluded from the Analysis of Male Hypogonadism
- Risk/Protective Factors
- Risk/Protective Factors for Male Hypogonadism
- Literature Review
Author(s): Nishant Kumar, MPH
Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects.
His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.